{
    "nct_id": "NCT06069570",
    "official_title": "Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination with Low Dose Radiotherapy in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer or Solid Tumors with Bone Metastases",
    "inclusion_criteria": "* Signed and dated informed consent form.\n* Male or female, > 18 years old.\n* Minimum body weight of 50 kilograms (kg).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically or cytologically confirmed locally advanced or metastatic NSCLC or locally advanced or metastatic solid tumor with bone metastasis\n* Progressed on SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors (NSCLC), and are not a candidate for further standard anti-neoplastic therapy and/or have exhibited intolerance to and/or declined clinically applicable salvage therapies, and/or have declined therapy.\n* Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriate target-directed molecular therapy.\n* At least one measurable target lesion based on RECIST v1.1 confirmed by radiological imaging. Participants with isolated bone metastases are eligible for enrollment are not required to have measurable disease\n* All toxicity associated with previous treatments are recovered to CTCAE grade of ≤1, except for continuing alopecia.\n* Adequate hematopoietic, hepatic and renal function\n* Agree to adequate contraception for up to 120 days after the last dose of study drug.\n* Negative serum pregnancy test for women of childbearing potential\n* All primary and metastatic disease sites are amenable to LDRT\n* For solid tumors with bone metastases subjects (Part 2 Cohort B): receiving zoledronic acid for solid tumors with bone metastases\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Chemotherapy, investigational, and/or check-point inhibitor therapy within the 30 days prior to study Day 1.\n* Major surgery, except for vascular access placement, within the 30 days prior to study Day 1.\n* Active autoimmune disease requiring immunosuppressive therapy.\n* Infection requiring systemic treatment within 30 days prior to study Day 1.\n* History of peritoneal effusion (ascites), pericardial, or pleural effusions/nodules.\n* Uncontrolled hypertension, history of arrhythmia including atrial fibrillation, unstable angina, decompensated congestive heart failure, cardiac ejection fraction ≤ 50%, myocardial infarction, or marked baseline prolonged QT/QTc intervals.\n* Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C detection.\n* Participation in the treatment portion of a clinical trial or completed a clinical trial within the 30 days prior to the first dose of KB-GDT-01.\n* Presence of any condition that may, in the opinion of the Investigator, render the patient inappropriate from participating in the study.\n* Breastfeeding or pregnant female, or patient is expecting to conceive or father children during the study.\n* Allergy or intolerance to any of the study product ingredients or excipients.\n* Live vaccines administered within 30 days prior to study Day 1.\n* Individuals lacking capacity to consent for themselves.\n* Superior vena cava obstruction\n* Prior radiation therapy to a selected LDRT treatment site </= 30 days prior to Day 1.",
    "miscellaneous_criteria": ""
}